Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 133, Issue 6
February 7 2019
Issue Cover

Table of Contents

BLOOD COMMENTARIES

CLINICAL TRIALS AND OBSERVATIONS
Ravulizumab: a complementary option for PNH
Clinical Trials & Observations
Nathan T. Connell
View Articletitled, Ravulizumab: a complementary option for PNH
Lymphoid Neoplasia
Functional profiling to improve therapy in TCL
Kojo S. J. Elenitoba-Johnson
View Articletitled, Functional profiling to improve therapy in TCL
MYELOID NEOPLASIA
Roman warfare: targeting of support cells in AML
Catherine C. Smith
View Articletitled, Roman warfare: targeting of support cells in AML
THROMBOSIS AND HEMOSTASIS
Challenging the concept of immunothrombosis
Raghavendra Palankar,Andreas Greinacher
View Articletitled, Challenging the concept of immunothrombosis

REVIEW ARTICLE

The multifaceted role of fibrinogen in tissue injury and inflammation
James P. Luyendyk,Jonathan G. Schoenecker,Matthew J. Flick
View Articletitled, The multifaceted role of fibrinogen in tissue injury and inflammation

HOW I TREAT

How I treat MDS after hypomethylating agent failure
Clinical Trials & Observations
Valeria Santini
View Articletitled, How I treat MDS after hypomethylating agent failure

CLINICAL TRIALS AND OBSERVATIONS

Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study
Clinical Trials & Observations
Jong Wook Lee,Flore Sicre de Fontbrune,Lily Wong Lee Lee,Viviani Pessoa,Sandra Gualandro,Wolfgang Füreder,Vadim Ptushkin,Scott T. Rottinghaus,Lori Volles,Lori Shafner,Rasha Aguzzi,Rajendra Pradhan,Hubert Schrezenmeier,Anita Hill

There is a Blood Commentary on this article in this issue.

View Articletitled, Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study
Supplemental data
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study
Clinical Trials & Observations
Austin G. Kulasekararaj,Anita Hill,Scott T. Rottinghaus,Saskia Langemeijer,Richard Wells,F. Ataulfo Gonzalez-Fernandez,Anna Gaya,Jong Wook Lee,Emilio Ojeda Gutierrez,Caroline I. Piatek,Jeff Szer,Antonio Risitano,Shinji Nakao,Eric Bachman,Lori Shafner,Andrew I. Damokosh,Stephan Ortiz,Alexander Röth,Regis Peffault de Latour

There is a Blood Commentary on this article in this issue.

View Articletitled, Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy
Tatjana Bilich,Annika Nelde,Leon Bichmann,Malte Roerden,Helmut R. Salih,Daniel J. Kowalewski,Heiko Schuster,Chih-Chiang Tsou,Ana Marcu,Marian C. Neidert,Maren Lübke,Jonas Rieth,Mirle Schemionek,Tim H. Brümmendorf,Vladan Vucinic,Dietger Niederwieser,Jens Bauer,Melanie Märklin,Janet K. Peper,Reinhild Klein,Oliver Kohlbacher,Lothar Kanz,Hans-Georg Rammensee,Stefan Stevanović,Juliane S. Walz
View Articletitled, The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy
Supplemental data

LYMPHOID NEOPLASIA

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas
Raphael Koch,Amanda L. Christie,Jennifer L. Crombie,Adam C. Palmer,Deborah Plana,Kay Shigemori,Sara N. Morrow,Alexandria Van Scoyk,Wenchao Wu,Elizabeth A. Brem,J. Paul Secrist,Lisa Drew,Alwin G. Schuller,Justin Cidado,Anthony Letai,David M. Weinstock

There is a Blood Commentary on this article in this issue.

View Articletitled, Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas
Supplemental data
Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study
Florent Joly,Camille Cohen,Vincent Javaugue,Sébastien Bender,Mohamed Belmouaz,Bertrand Arnulf,Bertrand Knebelmann,Mathilde Nouvier,Vincent Audard,François Provot,Viviane Gnemmi,Dominique Nochy,Jean Michel Goujon,Arnaud Jaccard,Guy Touchard,Jean Paul Fermand,Christophe Sirac,Frank Bridoux
View Articletitled, Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study
Supplemental data

MYELOID NEOPLASIA

CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells
David K. Edwards, V,Kevin Watanabe-Smith,Angela Rofelty,Alisa Damnernsawad,Ted Laderas,Adam Lamble,Evan F. Lind,Andy Kaempf,Motomi Mori,Mara Rosenberg,Amanda d’Almeida,Nicola Long,Anupriya Agarwal,David Tyler Sweeney,Marc Loriaux,Shannon K. McWeeney,Jeffrey W. Tyner
View Articletitled, CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells
Supplemental data

THROMBOSIS AND HEMOSTASIS

Salmonella-induced thrombi in mice develop asynchronously in the spleen and liver and are not effective bacterial traps
Brief Report
Nonantzin Beristain-Covarrubias,Marisol Perez-Toledo,Adriana Flores-Langarica,Malou Zuidscherwoude,Jessica R. Hitchcock,Will M. Channell,Lloyd D. W. King,Mark R. Thomas,Ian R. Henderson,Julie Rayes,Steve P. Watson,Adam F. Cunningham
View Articletitled, <em>Salmonella</em>-induced thrombi in mice develop asynchronously in the spleen and liver and are not effective bacterial traps
Supplemental data

TRANSFUSION MEDICINE

Plateletpheresis-associated lymphopenia in frequent platelet donors
Clinical Trials & Observations
John M. Gansner,Mahboubeh Rahmani,A. Helena Jonsson,Brooke M. Fortin,Idayat Brimah,Martha Ellis,Robin Smeland-Wagman,Zhihan J. Li,Jason M. Schenkel,Michael B. Brenner,Revital Yefidoff-Freedman,Steven R. Sloan,Nancy Berliner,Nicolas C. Issa,Lindsey R. Baden,Dan L. Longo,Duane R. Wesemann,Donna Neuberg,Deepak A. Rao,Richard M. Kaufman
View Articletitled, Plateletpheresis-associated lymphopenia in frequent platelet donors
Supplemental data

LETTER TO BLOOD

Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis
Clinical Trials & Observations
Michael R. DeBaun,Djamila L. Ghafuri,Mark Rodeghier,Poulami Maitra,Shruti Chaturvedi,Adetola Kassim,Kenneth I. Ataga
View Articletitled, Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis

BLOOD WORK

Marrow involvement by metastatic spindle cell angiosarcoma
Wing Kit Lam,Sze Fai Yip
View Articletitled, Marrow involvement by metastatic spindle cell angiosarcoma
Relapse of multiple myeloma presenting as pericardial effusion
Justine Onraed,Thomas Boyer
View Articletitled, Relapse of multiple myeloma presenting as pericardial effusion

ERRATUM

Ren W, Ye X, Su H, et al. Genetic landscape of hepatitis B virus–associated diffuse large B-cell lymphoma. Blood. 2018;131(24):2670-2681.
View Articletitled, Ren W, Ye X, Su H, et al. Genetic landscape of hepatitis B virus–associated diffuse large B-cell lymphoma. <em>Blood</em>. 2018;131(24):2670-2681.
All Issues

Advertisement intended for health care professionals

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma
Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation
Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation
Prothrombotic Antibodies Targeting the Spike Protein's Receptor-Binding Domain in Severe COVID-19
The Contribution of the Monocyte‐Macrophage Lineage to Immunotherapy Outcomes

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals